Who are Recombinant birch pollen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tree 12 SQ-Bet, Cupressus arizonica, Staloral 300, Novel dose adjustment of Alutard SQ, HDM 12 SQ-HDM, ragweed pollen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-birch-pollen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Recombinant birch pollen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recombinant birch pollen (Recombinant birch pollen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy. Area: Immunology / Allergy.

phase 3 Allergen immunotherapy Birch pollen allergens (Bet v 1 and related epitopes) Immunology / Allergy Biologic Live · refreshed every 30 min

Target snapshot

Recombinant birch pollen (Recombinant birch pollen) — Allergopharma GmbH & Co. KG. Recombinant birch pollen allergen extract desensitizes the immune system to birch pollen through repeated controlled exposure, reducing allergic responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Recombinant birch pollen TARGET	Recombinant birch pollen	Allergopharma GmbH & Co. KG	phase 3	Allergen immunotherapy	Birch pollen allergens (Bet v 1 and related epitopes)
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
Cupressus arizonica	Cupressus arizonica	Laboratorios Leti, S.L.	marketed	Allergen immunotherapy
Staloral 300	Staloral 300	Medical University of Lodz	marketed	Allergen immunotherapy (sublingual tablet)	Grass pollen allergens (Phleum pratense and related species)
Novel dose adjustment of Alutard SQ	Novel dose adjustment of Alutard SQ	Beijing Tongren Hospital	marketed	Allergen immunotherapy
HDM 12 SQ-HDM	HDM 12 SQ-HDM	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	House dust mite allergens (Der p 1, Der p 2, Der f 1, Der f 2)
ragweed pollen	ragweed pollen	The University of Texas Medical Branch, Galveston	marketed	Allergen immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy class)

Allergopharma GmbH & Co. KG · 8 drugs in this class
HAL Allergy · 2 drugs in this class
Medical University of Silesia · 2 drugs in this class
ALK-Abelló A/S · 2 drugs in this class
Laboratorios Leti, S.L. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Royal Sussex County Hospital · 1 drug in this class
The University of Texas Medical Branch, Galveston · 1 drug in this class
University of Genova · 1 drug in this class
Anergis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant birch pollen — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-birch-pollen. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing